Evidence map›Paper›PMID 37158084›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2023

The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus.

I Barrutieta-Arberas, N Ortuzar, A Vaquero-Rodríguez, M Picó-Gallardo, H Bengoetxea, M A Guevara, P A Gargiulo, J V Lafuente

Open access · greenAbstract readReview
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation.International journal of molecular sciences · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

I Barrutieta-ArberasLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.ORCID 0000-0002-7643-349X
N OrtuzarLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
A Vaquero-RodríguezLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.ORCID 0000-0002-9118-3177
M Picó-GallardoLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
H BengoetxeaLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
M A GuevaraLaboratory of Neurosciences and Experimental Psychology, Area of Pharmacology, Department of Pathology, Faculty of Medical Sciences, National Council of Scientific and Technical Research, National University of Cuyo, 5502 Mendoza, Argentina.
P A GargiuloLaboratory of Neurosciences and Experimental Psychology, Area of Pharmacology, Department of Pathology, Faculty of Medical Sciences, National Council of Scientific and Technical Research, National University of Cuyo, 5502 Mendoza, Argentina.
J V LafuenteLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
University of the Basque Country · ESUniversidad Nacional de Cuyo · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major depressive disorder (MDD) is a complex illness that is arising as a growing public health concern. Although several brain areas are related to this type of disorders, at the cellular level, the parvalbumin-positive cells of the hippocampus interplay a very relevant role. They control pyramidal cell bursts, neuronal networks, basic microcircuit functions, and other complex neuronal tasks involved in mood disorders. In resistant depressions, the efficacy of current antidepressant treatments drops dramatically, so the new rapid-acting antidepressants (RAADs) are being postulated as novel treatments. Ketamine at subanesthetic doses and its derivative metabolites have been proposed as RAADs due to their rapid and sustained action by blocking

Indexed as

KetamineMajor Depressive DisorderAntidepressive AgentsBrain-Derived Neurotrophic FactorHippocampusHumansInterneuronsParvalbuminsReceptors, N-Methyl-D-AspartateAntidepressive AgentsBrain-Derived Neurotrophic FactorKetamineParvalbuminsReceptors, N-Methyl-D-Aspartatebrain-derived neurotrophic factor (BDNF)hippocampus (HC)interneurons (INs)ketaminemajor depressive disorder (MDD)N-methyl-d-aspartate receptors (NMDARs)

Identifiers

PMID37158084
PMCPMC10350797
OpenAlexW4375949514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.